Coxor™ is a powder and solvent for oral solution for emergency treatment for suspected acute myocardial infarction. This medicine is used in adults above 18 years for suspected acute myocardial infarction (heart attack) after contact with emergency medical services. In case of symptoms of a suspected acute myocardial infarction, the patient should call the national rescue number as soon as possible. If advised to do so by the emergency medical services, 300 mg of Coxor™ should be taken as quickly as possible. The content is to be drunk following reconstitution. The powder is to be dissolved in the solvent and shaken until it is dissolved. Medicinal product not subject to medical prescription
Coxor is designed to be ready-to-use and simple to self-administer for all-risk patient groups.
Asamedic started production of the drug in the fall of 2018 and set 6,000 vials in stability program. Full scale production started november 2020.
DCP well-established use application was submitted in 2019 and approved in 2021 with Norway as RMS and Denmark as CMS.
Endorsed by the authorities and key opinion leaders, Coxor was successfully launched in Norway in 2023. More countries to follow.
“ASA administered alone quickly after chest pain begins reduces mortality in heart attack by 23%.”ISIS-2 (Second International Study of lnfarct Survival) Collaborative Group (1988) 5).”
“In a critical situation, ASA should be provided in a solution with rapid onset of action.”Wollard et al, «Life saving early and immediate aspirin: too little too late»
“After five minutes, the level of ASA in the blood is 15x larger with a fluid than with a tablet.”Muir et al, «The influence of dosing form on aspirin kinetics: implications for acute cardiovascular use»
“Barbash et al found in their study from 2002 that mortality rate of people receiving first ASA dose late was 2.26 times higher than the people receiving ASA early ”Barbash I, Freimark D, Gottlieb S, Hod H, Hasin Y, Battler A, Crystal E, Matetzky S, Boyko V, Mandelzweig L, Behar S, Leor J; Israeli working group on intensive cardiac care, Israel heart society. Outcome of myocardial infarction in patients treated with aspirin is enhanced by pre-hospital administration. Cardiology. 2002;98(3):141-7. doi: 10.1159/000066324. PMID: 12417813.
The use of acetylsalicylic acid as self-medication for heart attacks is not currently widely promoted, even though its use is advised by the expert community. Coxor™ is the first liquid of its kind to be marketed for this purpose alone.
Coxor™ enables immediate intake of acetylsalicylic acid
When administered orally, acetylsalicylic acid can be very rapidly absorbed, depending on formulation. Coxor is specifically designed for rapid onset of action, crucial in cases of suspected myocardial infarction.
Coxor™ enables immediate intake of acetylsalicylic acid without needing a glass of water and does not depend on the patient’s saliva production.
Coxor™ is the first dedicated emergency OTC approved product against heart attack with appropriate user properties.
Coxor study completed with positive outcome in 2022. Here is a link to the peer-reviewed published article.
Extensive investment projects and studies performed to secure patent protection — patent approved in Europe, USA, Australia, India and many other countries around the world.
Randomised Trial of Intravenous Streptokinase, Oral Aspirin, Both, or Neither Among 17 187 Cases of Suspected Acute Myocardial Infarction: ISIS-2 ISIS-2 (Second International Study of lnfarct Survival) Collaborative Group (1988), The Lancet 332 (8607): 349–360
Life saving early and immediate aspirin: too little too late Wollard et al, British Medical Journal, 2008 Vol 84, No 993
The influence of dosing form on aspirin kinetics: implications for acute cardiovascular use Muir et al, Curr Med Opinion 1997;13:547–53.
Investigation of paramedics’ compliance with clinical practice guidelines for the management of chest pain Figgis et al, Emergency Medical Journal, 2010, 27:151-155